Literature DB >> 8769896

Passage of a delta-opioid receptor selective enkephalin, [D-penicillamine2,5] enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers.

S A Williams1, T J Abbruscato, V J Hruby, T P Davis.   

Abstract

[D-Penicillamine2,5] enkephalin (DPDPE) is an enzymatically stable, delta-opioid receptor-selective peptide, which produces analgesia when given intracerebroventricularly. However, because only modest analgesic effects were seen after subcutaneous administration of DPDPE, it has been inferred that it does not cross the blood-brain barrier well. In this present study, a vascular brain perfusion technique in anesthetized rats was used to measure directly whether [3H]DPDPE could cross the blood-brain and/or the blood-CSF barriers. The results indicated that the brain uptake of [3H]DPDPE was significantly greater than that of [14C]sucrose, a vascular marker (p < 0.01), and than that of [3H]DPDPE into the CSF (p < 0.01). Furthermore, HPLC analysis confirmed the integrity of the 3H to DPDPE and demonstrated that intact [3H]DPDPE entered the brain. Although 1 mM leucine-enkephalin failed to inhibit uptake of [3H]DPDPE, unlabeled DPDPE (100 microM) caused a significant inhibition of the brain uptake (p < 0.01) but not the CSF uptake of [3H]DPDPE. These data provide evidence that intact [3H]DPDPE enters the CNS of anesthetized rats by saturable and nonsaturable mechanisms. In addition, the saturable mechanism is likely to be found at the blood-brain barrier, with the blood-CSF barrier playing only a minor role in the brain uptake of this peptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769896     DOI: 10.1046/j.1471-4159.1996.66031289.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  Protecting motor networks during perinatal ischemia: the case for delta-opioid receptors.

Authors:  Stephen M Johnson; Sara M F Turner
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

2.  Deltorphin transport across the blood-brain barrier.

Authors:  A Fiori; P Cardelli; L Negri; M R Savi; R Strom; V Erspamer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 3.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 4.  Peptides at the blood brain barrier: Knowing me knowing you.

Authors:  Thomas P Davis; Thomas J Abbruscato; Richard D Egleton
Journal:  Peptides       Date:  2015-04-30       Impact factor: 3.750

Review 5.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

6.  Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases.

Authors:  B T Hawkins; T F Lundeen; K M Norwood; H L Brooks; R D Egleton
Journal:  Diabetologia       Date:  2006-12-02       Impact factor: 10.122

7.  Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

8.  A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.

Authors:  Sheng Zhang; Sijiu Liu; Rongya Tao; Dan Wei; Lan Chen; Weihua Shen; Zhi-Hong Yu; Lina Wang; David R Jones; Xiaocheng C Dong; Zhong-Yin Zhang
Journal:  J Am Chem Soc       Date:  2012-10-17       Impact factor: 15.419

Review 9.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

10.  Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Harry Pieter De Koning; Sarah Ann Thomas
Journal:  J Pharmacol Exp Ther       Date:  2009-03-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.